Lv52
888 积分 2026-03-20 加入
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
8天前
已完结
Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohnʼs Disease
9天前
已完结
Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
11天前
已完结
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
11天前
已完结
Hyperactivation of sympathetic nerves fuels basophil infiltration in atopic dermatitis
14天前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
16天前
已完结
Atopic dermatitis
16天前
已完结
Characteristics and Regulation of Human Eosinophil ETosis In Vitro
20天前
已完结
Barriers for orally inhaled therapeutic antibodies
22天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
23天前
已完结
皖公网安备34019202002308
